We have our own point of view on the people, technologies, and conversations that will shape the future.
Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.
Delfi Diagnostics has developed a test that combines ultra-low-cost sequencing and machine learning to detect cancer early.
Recursion is a breakthrough drug discovery company that combines a novel computer vision platform with deep disease biology and chemistry.
Cancer remains one of the leading causes of death in the U.S. and worldwide.
Ophelia is reinventing addiction treatment and dramatically improving access to best-in-class care with telemedicine.
In the face of a national emergency in child and adolescent mental health, urgent measures are needed to help those in need.
Attention Digital Health Founders: We are now accepting applications to attend the Digital Health Founder’s Fellowship
Riva’s mission is to improve cardiovascular disease worldwide using just the smartphones that people already have in their pockets, replacing 130-year-old blood pressure cuff technology.
Insurtech has been hot—at least seven venture-backed insurers will have gone public since the second half of 2020.
Opioid use disorder (OUD) is an epidemic that will define our generation. Roughly 90 million Americans use opioids and over 10 million misuse them.
We believe purpose-built vertical SaaS will help make drug discovery more effective and efficient and ultimately improve healthcare outcomes.
Here at Menlo, we are building an investing practice focused on three of the most exciting areas of healthcare: therapeutic platforms, digital health, and transformative technologies.
Nearly half of U.S. adults—108 million people—have high blood pressure, which is the #1 controllable risk for both heart disease and stroke, the two leading worldwide causes of death.
As part of the 21st Century Cures Act, the White House established rules compelling payers and hospitals to make patient health data easily shareable by modern technology standards.
H1 is a unique healthcare data SaaS company with proprietary data, compelling initial applications, and potential to expand.
Today we launch our 15th venture fund, Menlo XV, a flagship $500M fund to help early-stage founders transform existing industries, create new categories, and build a better future.